Other Events ·
RedHill Biopharma rescheduled its annual general meeting from July 28, 2026, to August 6, 2026, to include an…
RDHLRedHill Biopharma Ltd.
RedHill Biopharma rescheduled its annual general meeting from July 28, 2026, to August 6, 2026, to include an additional proposal. Shareholders will vote on re-appointing Kesselman & Kesselman as auditors, re-electing directors Rick D. Scruggs and Dr. Shmuel Cabilly for three-year terms, and approving the engagement of Dror Ben-Asher as both Chairman and CEO for three years starting August 6, 2026. Additionally, the company proposes amending its Articles of Association to eliminate the par value of its shares to increase administrative flexibility. The record date for voting is July 2, 2026. The company operates in the biopharmaceutical industry and develops therapeutic drugs.